5 minFirst, clinical effect: efficacy and safety are equal, showing the potential of "Best-in-Class"
The preclinical data of ISM9528 is the central highlight of this announcement, and its efficacy and safety are outstanding.
Excellent pain relief
In multiple proven pain models, ISM9528 demonstrated the strong analgesic effect of dose-dependent as an oral drug:
In the neuropathic pain model of chiropractic ligation (SNL) in rats, the median dose of ISM9528 produced significant analgesic effects for up to six hours after administration, comparable to the standard treatment drug pribalin.
In the postoperative acute pain model , ISM9528 took effect rapidly 0.5 hours after administration, better efficacy than the equivalent dose of prebarin .
Even more exciting is that in some models, its analgesic potential is comparable to or even greater than opioid morphine.
The following figure visually compares the analgesic effect of ISM9528 with pregabalin and morphine in the SNL model:
Data source: This figure is schematic based on qualitative descriptions such as "Effectiveness is Better Than Pribarin" and "Comparative or even more than morphine" in the official press release of Insilicon Intelligence (July 2026). 75%, 55%, 70% are indicative values, which is designed to visually reflect the relative curvature relationship, and the specific precise data should be based on the original research finally published by the silicon intelligence.
Good security features
In both in vitro and in vivo safety screening covering multiple strains, ISM9528 showed excellent tolerability:
Good safety window : 28-day rat study shows a margin of safety of about 41.5 times, 28-day dog studies show a margin of safety of about 57.5 times (source: Bioworld report)
Low risk of cardiotoxicity : hERG inhibits concentration above 10 μM, much higher than clinically expected exposure levels
No genotoxicity: the genotoxicity test result is negative
The most important thing is that you don't have the characteristics of addiction that are typical of opioids.
The following figure compares the risk difference between ISM9528 and opioids in a critical safety dimension:
ata source notes: Safety window data (41.5 times for rats, 57.5 times for dogs) are from BioWorld's detailed report on InSilicon's press release; hERG and genotoxicity data are from InSilicon's official statement. Risk comparison values are presented illustratively based on descriptions such as "not exhibiting opioid addiction characteristics."
II. Milestone Significance: Validating AI's Ability to Discover "First-in-Class" New Targets
The nomination of ISM9528 is significant beyond the advancement of a single pipeline, demonstrating the transformative power of AI-driven pharmaceuticals from multiple dimensions.
Successfully unlocking a brand-new mechanism demonstrates the capabilities of AI in target discovery.
Target Z, which targets ISM9528, is a novel target that has never been systematically linked to pain management before. PandaOmics, an AI engine from InSilicon Intelligence, precisely identified the key link between this target and pain by analyzing massive amounts of omics and textual data, significantly shortening the target discovery process, which traditionally takes years , to just a few months .
Strong evidence of the reproducibility and scalability of AI-powered drug development platforms
ISM9528 is the 31st preclinical candidate compound nominated by InSilicon Intelligence since 2021 , of which 13 have already received IND approval. The high efficiency of its AI platform is fully demonstrated in the data.
Data Source Notes: The data in this chart comes from Insilicon's official press release. The time taken and number of molecules synthesized in the traditional model are based on industry consensus (traditional drug discovery typically takes 2.5-4 years and synthesizes thousands of molecules), and are not official data from Insilicon.
The "Eureka Moment" in Overcoming the Challenge of Non-Opioid Analgesia
More than 20% of the global population suffers from chronic pain, while existing treatments face challenges such as addiction or gastrointestinal toxicity. Preclinical data from ISM9528 points to an exciting new direction for developing highly effective, safe, and non-addictive novel analgesics. Dr. Carol Satler, Chief Scientific Officer of InSilicon Intelligence, calls this a "Eureka moment" that will revolutionize patient care .
III. Company's Next Steps: Accelerate the process, aiming for clinical trials in 2027.
Based on encouraging preclinical data, Insilicon has developed a clear roadmap for the future:
Key step : The company plans to initiate a GLP toxicology study in October 2026 to support its Investigational New Drug (IND) application.
Clinical Goal : After completing the necessary preclinical studies, Insilicon aims to advance ISM9528 to the human clinical trial stage by 2027 .
If subsequent clinical studies can replicate the positive preclinical results, ISM9528 has the potential to become a disruptive therapy in the field of pain management , meeting the huge unmet medical needs worldwide and validating the transformative power of AI in the discovery of novel targets and the development of "first-in-class" drugs.
